Physician

Hussein El-Newihi, MD

According to 2025 Medicare claims, Hussein El-Newihi, MD (NPI: 1275580698) practices gastroenterology in the El Centro, CA market, with the plurality of this provider's patient population coming from Imperial, CA. This provider's primary affiliated billing organization is IMPERIAL VALLEY FAMILY CARE MEDICAL GROUP APC (NPI: 1275581894; TIN: 330652678) and primary practice location at 92243-4242. El-Newihi is affiliated with the Aledade 60 CA MSSP Enhanced (ACO ID: A4775) and Concord Hospital ACO, LLC (ACO ID: A4984), participating under the MSSP model.

El-Newihi's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 1,432 traditional Medicare patients, billed 3,464 HCPCS/CPT codes, and received $270,849 in Medicare payments. The top billing code was 45385 (Removal of polyps or growths of large bowel using an endoscope with mechanical snare). Part D data shows 4,882 prescription claims across 1,627 beneficiaries totaling $1,016,880 in drug costs, led by Ocaliva (Obeticholic Acid). 2022 DME data shows 22 claims. Open Payments data shows 38 records totaling $1,201. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has declined steadily, from $391,791 to $270,849. Similarly, Part D prescription costs started with an early spike, then settled into a lower baseline, moving from $2,235,140 to $1,016,880. For DME billing, this provider has fewer than 5 years of reported data, so a reliable trend cannot be assigned.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	1,857	4,076	$391,791
2016	2,053	4,691	$408,089
2017	2,035	5,028	$390,326
2018	1,917	4,871	$359,090
2019	1,882	5,281	$370,289
2020	1,538	4,169	$286,096
2021	1,476	3,748	$292,965
2022	1,445	3,791	$284,868
2023	1,355	3,341	$254,884
2024	1,432	3,464	$270,849

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	926	6,567	$2,235,140
2016	998	7,520	$2,674,665
2017	998	6,736	$2,037,541
2018	955	6,234	$1,684,588
2019	877	5,789	$1,306,359
2020	1,386	5,745	$1,052,736
2021	829	4,626	$1,011,278
2022	1,487	5,320	$913,704
2023	1,460	4,965	$931,702
2024	1,627	4,882	$1,016,880

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	N/R	81	$8,377
2016	N/R	81	$5,246
2017	N/R	79	$4,098
2018	N/R	42	$3,132
2019	N/R	N/R	N/R
2020	N/R	N/R	N/R
2021	N/R	26	$692
2022	N/R	22	$644
2023	N/R	N/R	N/R
2024	N/R	N/R	N/R

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
45385	Removal of polyps or growths of large bowel using an endoscope with mechanical snare	230	230	$174
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	476	675	$96
43239	Biopsy of esophagus, stomach, and/or upper small bowel using a flexible endoscope	241	241	$82
99213	Established patient office or other outpatient visit with low level od decision making, if using time, 20 minutes or more	528	698	$68
G0500	Moderate sedation services provided by the same physician or other qualified health care professional performing a gastrointestinal endoscopic service that sedation supports, requiring the presence of an independent trained observer to assist in the monito	664	702	$4

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Ocaliva	Obeticholic Acid	31	930	$280,444
Linzess	Linaclotide	122	5,460	$95,344
Cimzia (2 Pack)	Certolizumab Pegol	13	364	$69,589
Creon	Lipase/Protease/Amylase	21	1,049	$52,352
Xifaxan	Rifaximin	12	340	$35,754

Top 5 DME services in 2024

No connected or detailed DME service-level records for 2024.

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	38	$1,201	Phathom Pharmaceuticals, Inc.
Research Payments	Reported research-related payment or transfer-of-value amount.	0	$0	N/R
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Hussein El-Newihi, MD?

Tedicare shows public-source Medicare data for Hussein El-Newihi, MD (NPI 1275580698), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Hussein El-Newihi, MD have ACO affiliation data?

Hussein El-Newihi, MD is shown with ACO affiliation data for Aledade 60 CA MSSP Enhanced (MSSP, ACO ID A4775) and Concord Hospital ACO, LLC (MSSP, ACO ID A4984).

What billing organization is linked to Hussein El-Newihi, MD?

Hussein El-Newihi, MD is linked to IMPERIAL VALLEY FAMILY CARE MEDICAL GROUP APC (billing NPI 1275581894) in the available physician profile data.

Does Hussein El-Newihi, MD have Open Payments data?

Hussein El-Newihi, MD has 38 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.